D
Dongrui Ray Lu
Researcher at Pfizer
Publications - 12
Citations - 2401
Dongrui Ray Lu is an academic researcher from Pfizer. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 2162 citations.
Papers
More filters
Journal ArticleDOI
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more
TL;DR: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
Journal ArticleDOI
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung Jue Bang,Yoon-Koo Kang,Won Ki Kang,Narikazu Boku,Hyun Cheol Chung,Jen-Shi Chen,Toshihiko Doi,Yan Sun,Lin Shen,Shukui Qin,Wai Tong Ng,Jennifer M. Tursi,Maria Jose Lechuga,Dongrui Ray Lu,Ana Ruiz-Garcia,Alberto Sobrero +15 more
TL;DR: The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunit inib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.
Journal ArticleDOI
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
Erica L. Mayer,Christian Fesl,Dominik Hlauschek,Laura García-Estévez,Harold J. Burstein,Nicholas Zdenkowski,Viktor Wette,Kathy D. Miller,Marija Balic,Ingrid A. Mayer,David Cameron,Eric P. Winer,Jose Juan Ponce Lorenzo,Diana Lake,Gunda Pristauz-Telsnigg,Tufia C. Haddad,Lois E. Shepherd,Hiroji Iwata,Matthew P. Goetz,Fatima Cardoso,Tiffany A. Traina,Danusha Sabanathan,Urs Breitenstein,Kerstin Ackerl,Otto Metzger Filho,Karin Zehetner,Kadine Solomon,Sarra El-Abed,Katherine P. Theall,Dongrui Ray Lu,Amylou C. Dueck,Michael Gnant,Angela DeMichele +32 more
TL;DR: Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure and the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.
Journal Article
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET)
Aaron I. Vinik,Eric Van Cutsem,Patricia Niccoli,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Jen-Shi Chen,D. Hoersch,Daniel Castellano,Hagen F. Kennecke,Joel Picus,Guy van Hazel,Shem Patyna,Dongrui Ray Lu,Richard C. Chao,Eric Raymond +19 more
TL;DR: This research highlights the need to understand more fully the role of “cell reprograming” in the development of Parkinson’s disease and its role in cancer.
Journal ArticleDOI
Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort
Angela DeMichele,Amylou C. Dueck,Dominik Hlauschek,Miguel Martin,Harold J. Burstein,Georg Pfeiler,Nicholas Zdenkowski,Antonio C. Wolff,Marija Balic,Kathy D. Miller,David Cameron,Justin M. Balko,Tiffany A. Traina,Dorota Czajkowska,Otto Metzger,Dongrui Ray Lu,P. O'Brien,Christian Fesl,Erica L. Mayer,Michael Gnant +19 more
TL;DR: The addition of adjuvant palbociclib to standard ET did not improve outcomes over ET alone, suggesting no benefit from the agent in reducing the incidence of early relapse in pts with lower-stage HR+/HER2- breast cancer.